Event Highlights: IMPACT 2020 R&D Day
On October 30th, IMPACT 2020 R&D Day was successfully held in Grand Hyatt Shanghai Hotel with a fascinating theme as "Hallmarks of Cancer and Synthetic Lethality". Scientific Advisory Board (SAB) members of IMPACT Therapeutics delivered keynote speeches in the morning, and the management team of IMPACT presented the latest product pipeline development in the afternoon. The event was broadcasted by live video simultaneously worldwide. More than four hundred people participated in this event onsite or online. Invited guests from investment firms, pharmaceutical companies, universities and institutes, and other life science industrial organizations, joined and witnessed this spectacular event.
On-site: IMPACT 2020 R&D Day
Dr. Jun Bao, President and CEO of IMPACT Therapeutics, gave opening remarks and introduced the hallmarks of cancer and the concept of synthetic lethality. One of the hallmarks of cancer is genome instability and mutation. PARP inhibitors have been developed as therapeutics targeted to this particular cancer hallmark. In addition, genome instability and mutation in cancer cells render them more dependent on alternative pathways so these cancer cells are more vulnerable to targeted therapeutic perturbations on those alternative pathways – a phenomenon known as synthetic lethality. At IMPACT, we have concentrated our R&D efforts on exploring synthetic lethality in cancer cells as a weapon to target hard-to-treat tumors.
Opening Remarks by Dr. Jun Bao
Next, the four SAB members of IMPACT Therapeutics successively gave academic presentations from different perspectives. They are Dr. Douglas Hanahan and Dr. Robert Weinberg, the co-authors of “The Hallmarks of Cancer”, Dr. Alan D. D'Andrea, an internationally acclaimed expert in the field of DNA damage and repair, and Dr. Andrew Zhu, a globally recognized key opinion leader in the clinical field of liver cancer. Under the theme of "Hallmarks of Cancer and Synthetic Lethality", these scientists and clinicians provided in-depth analysis in the mechanism of cancer development and progression, and proposed profound insights in anti-cancer therapeutics development strategy.
In the afternoon, Dr. Jun Bao made a speech titled“ Small Molecule, Big Impact - Building Global Leading Synthetic Lethality Product Pipeline” and shared the company pipeline progress with the audience. Dr. Bao introduced IMPACT unique three-step R&D strategy – establishing, dominating, and expanding. “Firstly, we selected PARP, a clinically validated target, as the first program to set a foundation for novel drug discovery and development capability. Secondly, we are driving internal DDR R&D programs which cover most known DDR targets with unique selectivity. Thirdly, we are initiating synthetic lethality R&D programs beyond DDR space.”
Subsequently, Dr. Chih-Yi Hsieh, Senior VP and Chief Medical Officer of IMPACT, reported the differentiated clinical development strategies and the latest data of PARP Inhibitor Senaparib program and Wee1 Inhibitor IMP7068 program. Dr. Hsieh said, “Our clinical development strategy is orientated by the unmet needs. We select precise biomarkers throughout development and design clinical trials for seamless transition between discrete development phases. We also actively communicate with regulatory authorities to apply for expedited programs. Our clinical development strategy with these core features will boost the progress and bring new drugs to the market faster, and eventually benefit cancer patients worldwide.
Finally, Dr. Jun Bao, Dr. Chih-Yi Hsieh, Dr. Suixiong Cai, co-founder and Chief Technology Officer of IMPACT, and Dr. Ye Edward Tian, co-founder and Chief Scientific Officer of IMPACT, participated in a roundtable discussion and had a lively academic discussion with the guests.
Panel discussion by IMPACT management team
From left: Dr. Jun Bao, Dr. Chih-Yi Hsieh, Dr. Suixiong Cai and Dr. Ye Edward Tian
The inaugural IMPACT 2020 R&D Day is a successful event, highly recognized by the attendees, to demonstrate R&D progress, to hear advice and to discuss potential collaborations. With all the support, Impact is dedicated in building a global leading synthetic lethality product pipeline to finally achieve the mission: Make an IMPACT on Cancer Treatment！